155 related articles for article (PubMed ID: 17361126)
1. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.
Berria R; Glass L; Mahankali A; Miyazaki Y; Monroy A; De Filippis E; Cusi K; Cersosimo E; Defronzo RA; Gastaldelli A
Clin Pharmacol Ther; 2007 Sep; 82(3):275-81. PubMed ID: 17361126
[TBL] [Abstract][Full Text] [Related]
2. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
3. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
[TBL] [Abstract][Full Text] [Related]
4. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
6. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Belcher G; Lambert C; Edwards G; Urquhart R; Matthews DR
Diabetes Res Clin Pract; 2005 Oct; 70(1):53-62. PubMed ID: 16002175
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.
Basu A; Jensen MD; McCann F; Mukhopadhyay D; Joyner MJ; Rizza RA
Diabetes Care; 2006 Mar; 29(3):510-4. PubMed ID: 16505497
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
12. Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
Lin KD; Lee MY; Feng CC; Chen BK; Yu ML; Shin SJ
Diabet Med; 2014 Nov; 31(11):1341-9. PubMed ID: 24797920
[TBL] [Abstract][Full Text] [Related]
13. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
[TBL] [Abstract][Full Text] [Related]
14. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
15. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
16. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Hollenberg NK
Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
[TBL] [Abstract][Full Text] [Related]
17. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
20. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Colca JR; VanderLugt JT; Adams WJ; Shashlo A; McDonald WG; Liang J; Zhou R; Orloff DG
Clin Pharmacol Ther; 2013 Apr; 93(4):352-9. PubMed ID: 23462886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
